CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2

References

• WHO. WHO’s COVID-19 dashboard. [accessed 2022 Mar 18]. https://covid19.who.int/.
   Google Scholar
• Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):1–13. doi:10.1126/science.abc1932.
   Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192. doi:10.1016/S1473-3099(20)30843-4.
   PubMed Web of Science ®Google Scholar
• Cook IF. Best vaccination practice and medically attended injection site events following deltoid intramuscular injection. Hum Vaccin Immunother. 2015;11(5):1184–1191. doi:10.1080/21645515.2015.1017694.
   PubMed Web of Science ®Google Scholar
• Strategic Advisory Group of Experts on Immunization - SAGE (WHO). Evidence assessment: sinovac/CoronaVac COVID-19 vaccine. [Reported 2021 Apr 29. https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf.
   Google Scholar
• Afkhami S, D’Agostino MR, Zhang A, Stacey HD, Marzok A, Kang A, Singh R, Bavananthasivam J, Ye G, Luo X, et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 2022;185(5):896–915.e19. doi:10.1016/j.cell.2022.02.005.
   PubMed Web of Science ®Google Scholar
• Mallapaty S. China’s COVID vaccines have been crucial - now immunity is waning. Nature. 2021;598(7881):398–399. doi:10.1038/d41586-021-02796-w.
   PubMed Web of Science ®Google Scholar
• Jantarabenjakul W, Chantasrisawad N, Puthanakit T, Wacharapluesadee S, Hirankarn N, Ruenjaiman V, Paitoonpong L, Suwanpimolkul G, Torvorapanit P, Pradit R, et al. Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdox1 nCov-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers. Asian Pac J Allergy Immunol. 2021. doi:10.12932/AP-250721-1197. Epub ahead of print.
   Web of Science ®Google Scholar
• WHO. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac. [Reported 2021 Oct 21]. https://apps.who.int/iris/handle/10665/346788.
   Google Scholar
• WHO. Vaccine efficacy, effectiveness and protection. [Reported 2021 July 14]. https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection.
   Google Scholar
• Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–222. doi:10.1016/S0140-6736(21)01429-X.
   PubMed Web of Science ®Google Scholar
• Palacios R, Batista AP, Albuquerque CSN, Patiño EG, Santos JP, Conde MTRP, Piorelli RO, Júnior LCP, Raboni SM, Ramos F, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. [Posted 2021 Apr 11]. SSRN. https://ssrn.com/abstract=3822780.
   Google Scholar
• Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, Khrisna CV, Sari RM, Setyaningsih L, Surachman F, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia. Vaccine. 2021;39(44):6520–6528. doi:10.1016/j.vaccine.2021.09.052.
   PubMed Web of Science ®Google Scholar
• Strategic Advisory Group of Experts on Immunization-SAGE (WHO). Working group on COVID-19 vaccines. Evidence assessment: Sinovac/CoronaVac COVID-19 vaccine. [Reported 2021 Apr 29]. https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf.
   Google Scholar
• Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875–884. doi:10.1056/NEJMoa2107715.
   PubMed Web of Science ®Google Scholar
• Sevinc SA, Metin S, Basi NB, Ling J, Cinar AS, Oba S. Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival. Epidemiol Infect. 2022;150:e35. doi:10.1017/S0950268822000267.
   PubMed Web of Science ®Google Scholar
• Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW, Tully DC, Washburne AD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055. doi:10.1126/science.abg3055.
   PubMed Web of Science ®Google Scholar
• Can G, Acar HC, Aydin SN, Balkan II, Karaali R, Budak B, Saltoglu N. Waning effectiveness of CoronaVac in real life: a retrospective cohort study in health care workers. Vaccine. 2022;40(18):2574–2579. doi:10.1016/j.vaccine.2022.03.032.
   PubMed Web of Science ®Google Scholar
• Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, Crispim MAE, Sales FCS, Hawryluk I, McCrone JT, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372(6544):815–821. doi:10.1126/science.abh2644.
   PubMed Web of Science ®Google Scholar
• Ranzani OT, Hitchings MDT, Dorion M, D’-Agostini TL, de Paula RC, de Paula OFP, Villela EFM, Torres MSS, de Oliveira SB, Schulz W, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. 2021;374(2015). doi:10.1136/bmj.n2015.
   PubMedGoogle Scholar
• Cerqueira-Silva T, Oliveira VA, Boaventura VS, Pescarini JM, Júnior JB, Machado TM, Flores-Ortiz R, Penna GO, Ichihara MY, de Barros JV, et al. Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study. Lancet Reg Health Am. 2022;6:100154. doi:10.1016/j.lana.2021.100154.
   PubMedGoogle Scholar
• Serrano-Coll H, Miller H, Guzmán C, Rivero R, Gastelbondo B, Miranda J, Galeano K, Montaña-Restrepo J, Mattar S. Effectiveness of the CoronaVac® vaccine in a region of the Colombian Amazon, was herd immunity achieved? Trop Dis Travel Med Vaccines. 2022;8(1):2. doi:10.1186/s40794-021-00159-x.
   PubMedGoogle Scholar
• Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, Borg R, Schulz WL, de Oliveira RD, da Silva PV, et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study. Lancet Reg Health Am. 2021;1:100025. doi:10.1016/j.lana.2021.100025.
   PubMedGoogle Scholar
• Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V. Analysis of the delta variant B.1.617.2 COVID-19. Clin Pract. 2021;11(4):778–784. doi:10.3390/clinpract11040093.
   PubMed Web of Science ®Google Scholar
• Suah JL, Husin M, Keng PS, Hwa B, Thevananthan T, Low EV, Appannan MR, Zin FM, Zin SM, Yahaya H, et al. Waning COVID-19 vaccine effectiveness for BNT162b2 and CoronaVac in Malaysia: an observational study. Int J Infect Dis. 2022;S1201-9712(22):00167–9. doi:10.1016/j.ijid.2022.03.028. Epub ahead of print.
   Google Scholar
• Cerqueira-Silva T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, Júnior JB, Paixão ES, Robertson C, Penna GO, Werneck GL, Barreto ML, et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat Med. 2022;28(4):838–843. doi:10.1038/s41591-022-01701-w. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Harvard Medical School. As coronavirus continues to spread, many questions and answers. [Reported 2022 Jan 6]. https://web.archive.org/web/20220111054542/https://www.health.harvard.edu/diseases-and-conditions/coronavirus-resource-center.
   Google Scholar
• McMenamin ME, Nealon J, Lin Y, Wong YJ, Cheung JK, Lau EHY, Wu P, Leung GM, Cowling BJ. Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong. Medrxiv. 2022. preprint. doi:10.1101/2022.03.22.22272769.
   Google Scholar
• Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, Al Khatib HA, Coyle P, Ayoub HH, Al Kanaani Z, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021;385(24):e83. doi:10.1056/NEJMoa2114114.
   PubMed Web of Science ®Google Scholar
• Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676–681. doi:10.1038/s41586-021-04388-0.
   PubMed Web of Science ®Google Scholar
• WHO. Covid-19 vaccine effectiveness assessment in Chile. [Reported 2021 Oct 25]. https://cdn.who.int/media/docs/default-source/blue-print/chile_rafael-araos_who-vr-call_25oct2021.pdf?sfvrsn=7a7ca72a_7.
   Google Scholar
• CDC. Understanding adverse events and side effects. [Reported 2021 Mar 30]. https://www.cdc.gov/vaccinesafety/ensuringsafety/sideeffects/index.html.
   Google Scholar
• Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, Yuki EFN, Pedrosa T, Fusco SRG, Rojo PT, Pereira RMR, Shinjo SK, Andrade DCO, et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. 2021;27(10):1744–1751. doi:10.1038/s41591-021-01469-5.
   PubMed Web of Science ®Google Scholar
• Esquivel-Valerio JA, Skinner-Taylor CM, Moreno-Arquieta IA, Cardenas-de la Garza JA, Garcia-Arellano G, Gonzalez-Garcia PL, Almaraz-Juarez FDR, Galarza-Delgado DA. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. Rheumatol Int. 2021;41(12):2105–2108. doi:10.1007/s00296-021-05017-9.
   PubMed Web of Science ®Google Scholar
• Karacin C, Eren T, Zeynelgil E, Imamoglu GI, Altinbas M, Karadag I, Basal FB, Bilgetekin I, Sutcuoglu O, Yazici O, et al. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Future Oncol. 2021;17(33):4447–4456. doi:10.2217/fon-2021-0597.
   PubMed Web of Science ®Google Scholar
• Zhang MX, Zhang TT, Shi GF, Cheng FM, Zheng YM, Tung TH, Chen HX. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021;20(7):891–898. doi:10.1080/14760584.2021.1925112.
   PubMed Web of Science ®Google Scholar
• Supangat SE, Nugraha MY, Qodar TS, Mulyono BW, Tohari AI. COVID-19 vaccines programs: adverse events following immunization (AEFI) among medical clerkship student in Jember, Indonesia. BMC Pharmacol Toxicol. 2021;22(1):58. doi:10.1186/s40360-021-00528-4.
   PubMed Web of Science ®Google Scholar
• Riad A, Sağıroğlu D, Üstün B, Pokorná A, Klugarová J, Attia S, Klugar M. Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey. J Clin Med. 2021;10(12):2629. doi:10.3390/jcm10122629.
   PubMed Web of Science ®Google Scholar
• WHO. Updated safety & immunogenicity of 3rd dose CoronaVac® (Sinovac). [Reported 2021 Oct 25]. https://cdn.who.int/media/docs/default-source/blue-print/developers_sinovac_who-vr-call_25oct2021.pdf?sfvrsn=1aabe8d8_7.
   Google Scholar
• Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, Wu Z, Jiang D, Deng X, Chu K, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22(4):483–495. doi:10.1016/S1473-3099(21)00681-2.
   PubMed Web of Science ®Google Scholar
• Durmaz K, Aykut Temiz S, Metin Z, Dursun R, Abdelmaksoud A. Allergic and cutaneous reactions following inactivated SARS-CoV-2 vaccine (CoronaVac®) in healthcare workers. Clin Exp Dermatol. 2022;47(1):171–173. doi:10.1111/ced.14896.
   PubMed Web of Science ®Google Scholar
• Akdaş E, İ̇lter N, Öğüt B, Erdem Ö. Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report. J Eur Acad Dermatol Venereol. 2021;35(8):e491–e493. doi:10.1111/jdv.17316.
   PubMed Web of Science ®Google Scholar
• Akdaş E, Öğüt B, Erdem Ö, Öztaş MO, İ̇lter N. Cutaneous reactions following CoronaVac COVID-19 vaccination: a case series of six healthcare workers from a single centre. J Eur Acad Dermatol Venereol. 2021;35(12):e861–e864. doi:10.1111/jdv.17592.
   PubMed Web of Science ®Google Scholar
• An QJ, Qin DA, Pei JX. Reactive arthritis after COVID-19 vaccination. Hum Vaccin Immunother. 2021;17(9):2954–2956. doi:10.1080/21645515.2021.1920274.
   PubMed Web of Science ®Google Scholar
• İ̇remli BG, Şendur SN, Ünlütürk U. Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: postvaccination ASIA syndrome. J Clin Endocrinol Metab. 2021;106(9):2600–2605. doi:10.1210/clinem/dgab373.
   PubMed Web of Science ®Google Scholar
• Saygılı ES, Karakilic E. Subacute thyroiditis after inactive SARS-CoV-2 vaccine. BMJ Case Rep. 2021;14(10):e244711. doi:10.1136/bcr-2021-244711.
   PubMedGoogle Scholar
• Leber HM, Sant’Ana L, Konichi da Silva NR, Raio MC, Tjmm M, Endo CM, Nascimento H, de Souza CE. Acute thyroiditis and bilateral optic neuritis following SARS-CoV-2 vaccination with CoronaVac: a case report. Ocul Immunol Inflamm. 2021;29(6):1200–1206. doi:10.1080/09273948.2021.1961815.
   PubMed Web of Science ®Google Scholar
• Rattanawong W, Akaratanawat W, Tepmongkol S, Chutinet A, Tantivatana J, Suwanwela NC. Acute prolonged motor aura resembling ischemic stroke after COVID -19 vaccination (CoronaVac): the first case report. J Headache Pain. 2021;22(1):93. doi:10.1186/s10194-021-01311-w.
   PubMed Web of Science ®Google Scholar
• Chuaychoosakoon C, Parinyakhup W, Tanutit P, Maliwankul K, Klabklay P. Shoulder injury related to Sinovac COVID-19 vaccine: a case report. Ann Med Surg (Lond). 2021;68:102622. doi:10.1016/j.amsu.2021.102622.
   PubMed Web of Science ®Google Scholar
• Soysal A, Gönüllü E, Karabayır N, Alan S, Atıcı S, Yıldız İ, Engin H, Çivilibal M, Karaböcüoğlu M. Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers. Hum Vaccin Immunother. 2021;17(11):3876–3880. doi:10.1080/21645515.2021.1953344.
   PubMed Web of Science ®Google Scholar
• Banaszkiewicz A, Radzikowski A. Efficacy, effectiveness, immunogenicity–are not the same in vaccinology. World J Gastroenterol. 2013;19(41):7217–7218. doi:10.3748/wjg.v19.i41.7217.
   PubMed Web of Science ®Google Scholar
• Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, Woodworth KR, Nahabedian JF, 3rd, Azziz-Baumgartner E, Gilboa SM, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641–1647. doi:10.15585/mmwr.mm6944e3.
   PubMed Web of Science ®Google Scholar
• Soysal A, Bilazer C, Gönüllü E, Barın E, Çivilibal M. Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy. Hum Vaccin Immunother. 2021;17(10):3484–3486. doi:10.1080/21645515.2021.1947099.
   PubMed Web of Science ®Google Scholar
• Maertens K, De Schutter S, Braeckman T, Baerts L, Van Damme P, De Meester I, Leuridan E. Breastfeeding after maternal immunisation during pregnancy: providing immunological protection to the newborn: a review. Vaccine. 2014;32(16):1786–1792. doi:10.1016/j.vaccine.2014.01.083.
   PubMed Web of Science ®Google Scholar
• Calil VMLT, Palmeira P, Zheng Y, Krebs VLJ, Carvalho WB, Carneiro-Sampaio M. CoronaVac can induce the production of anti-SARS-CoV-2 IgA antibodies in human milk. Clinics (Sao Paulo). 2021;76:e3185. doi:10.6061/clinics/2021/e3185.
   Google Scholar
• Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, Kieneker LM, Noordzij M, Pena MJ, Vries H, et al. COVID-19-Related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020;35(11):1973–1983. doi:10.1093/ndt/gfaa261.
   PubMed Web of Science ®Google Scholar
• Combe C, Kirsch AH, Alfano G, Luyckx VA, Shroff R, Kanbay M, van der Sande F, Basile C, EUDIAL Working Group of the ERA-EDTA. At least 156 reasons to prioritize COVID-19 vaccination in patients receiving in-centre haemodialysis. Nephrol Dial Transplant. 2021;36(4):571–574. doi:10.1093/ndt/gfab007.
   PubMed Web of Science ®Google Scholar
• Eren Sadioğlu R, Demir E, Evren E, Aktar M, Şafak S, Artan AS, Meşe S, Ağaçfidan A, Çınar G, Önel M, et al. Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients. Transpl Infect Dis. 2021;23(6):e13740. doi:10.1111/tid.13740.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Vyas M, de Vries EGE, Kanesvaran R, Giuliani R, Peters S. European society for medical oncology. The ESMO call to action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor Educate Ann Oncol. 2021;32(5):579–581. doi:10.1016/j.annonc.2021.01.068.
   PubMed Web of Science ®Google Scholar
• Yalçın TY, Topçu DI, Doğan Ö, Aydın S, Sarı N, Erol Ç, Kuloğlu ZE, Azap ÖK, Can F, Arslan H. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: prospective observational study. J Med Virol. 2022;94(1):279–286. doi:10.1002/jmv.27316.
   PubMed Web of Science ®Google Scholar
• Bayram A, Demirbakan H, Günel Karadeniz P, Erdoğan M, Koçer I. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol. 2021;93(9):5560–5567. doi:10.1002/jmv.27098.
   PubMed Web of Science ®Google Scholar
• Ulhaq ZS, Soraya GV, Indriana K, Devitasari R, Pradiptha IPY, Zulfikar DB, Uxiana V, Zulkarnain, Rachma LN, Arisanti D. The level of Ig anti-RBD SARS-CoV-2 after two doses of CoronaVac vaccine. J Med Virol. 2021. doi:10.1002/jmv.27390.
   PubMed Web of Science ®Google Scholar
• Şenol Akar Ş, Akçalı S, Özkaya Y, Gezginci FM, Cengiz Özyurt B, Deniz G, Karadağ Yalçın F, Özer D, Dündar Erbay P, Eser E, et al. Factors affecting side effects, seroconversion rates and antibody response after inactivated SARS-CoV-2 Vaccination in healthcare workers. Mikrobiyol Bul. 2021;55(4):519–538. Turkish. doi:10.5578/mb.20219705.
   PubMed Web of Science ®Google Scholar
• Lin X, Xu X, Zeng X, Xu L, Zeng Z, Huo X. Decreased vaccine antibody titers following exposure to multiple metals and metalloids in e-waste-exposed preschool children. Environ Pollut. 2017;220(Pt A):354–363. doi:10.1016/j.envpol.2016.09.071.
   PubMedGoogle Scholar
• Zhu Y, Xie J, Huang F, Cao L. Association between short-term exposure to air pollution and COVID-19 infection: evidence from China. Sci Total Environ. 2020;727:138704. doi:10.1016/j.scitotenv.2020.138704.
   PubMed Web of Science ®Google Scholar
• Travaglio M, Yu Y, Popovic R, Selley L, Leal NS, Martins LM. Links between air pollution and COVID-19 in England. Environ Pollut. 2021;268(Pt A):115859. doi:10.1016/j.envpol.2020.115859.
   PubMedGoogle Scholar
• Zhang S, Chen S, Xiao G, Zhao M, Li J, Dong W, Hu J, Yuan T, Li Y, Liu L. The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine. Environ Sci Pollut Res Int. 2022;29(9):13720–13728. doi:10.1007/s11356-021-16786-y.
   PubMed Web of Science ®Google Scholar
• Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, James W, Gordon S, Pepper MS. SARS-CoV-2 variants, vaccines, and host immunity. Front Immunol. 2022;12:809244. doi:10.3389/fimmu.2021.809244.
   PubMed Web of Science ®Google Scholar
• Chen Y, Shen H, Huang R, Tong X, Wu C. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. Lancet Infect Dis. 2021;21(8):1071–1072. doi:10.1016/S1473-3099(21)00287-5.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma Y, Xu Y, Liu J, Li X, Chen Y, Chen Y, Xie J, Xiao L, Xiang Z, et al. Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma. Emerg Microbes Infect. 2022;11(1):424–427. doi:10.1080/22221751.2022.2027219.
   PubMed Web of Science ®Google Scholar
• Lu L, Mok BW, Chen LL, Chan JM, Tsang OT, Lam BH, Chuang VW, Chu AW, Chan WM, Ip JD, et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin Infect Dis. 2021;ciab1041. doi:10.1093/cid/ciab1041. Epub ahead of print.
   Web of Science ®Google Scholar
• Souza WM, Amorim MR, Sesti-Costa R, Coimbra LD, Brunetti NS, Toledo-Teixeira DA, de Souza GF, Muraro SP, Parise PL, Barbosa PP, et al. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. Lancet Microbe. 2021;2(10):e527–e535. doi:10.1016/S2666-5247(21)00129-4.
   PubMedGoogle Scholar
• Fernández J, Bruneau N, Fasce R, Martín HS, Balanda M, Bustos P, Ulloa S, Mora J, Ramírez E. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies. J Med Virol. 2022;94(1):399–403. doi:10.1002/jmv.27310.
   PubMed Web of Science ®Google Scholar
• Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384(23):2212–2218. doi:10.1056/NEJMoa2105000.
   PubMed Web of Science ®Google Scholar
• Duarte LF, Gálvez NMS, Iturriaga C, Melo-González F, Soto JA, Schultz BM, Urzúa M, González LA, Vázquez Y, Ríos M, et al. Immune profile and clinical outcome of breakthrough cases after vaccination with an inactivated SARS-CoV-2 vaccine. Front Immunol. 2021;12:742914. doi:10.3389/fimmu.2021.742914.
   PubMed Web of Science ®Google Scholar
• Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol. 2022;94(1):39–41. doi:10.1002/jmv.27350.
   PubMed Web of Science ®Google Scholar
• Wang K, Jia Z, Bao L, Wang L, Cao L, Chi H, Hu Y, Li Q, Zhou Y, Jiang Y, et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature. 2022;603(7903):919–925. doi:10.1038/s41586-022-04466-x.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry: emergency use authorization for vaccines to prevent COVID-19. [Reported 2021 May 25]. https://www.fda.gov/media/142749/download.
   Google Scholar